Clinical Trial Update: Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial results update for Molnupiravir (MK-4482) in non-hospitalized adults with COVID-19; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease

Drugs mentioned

• Molnupiravir (molnupiravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Coronavirus Disease (COVID-19) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-06-28